cd33/cll1 dual car-nk cell
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 10, 2023 (NCT05987696)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Myeloid cell surface antigen CD33Immunity, passive
CD33 immunity, passive
- C-type lectin domain family 12 member AImmunity, passive
immunity, passive - cll1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05987696 | Phase 1 | Aug 10, 2023 | China Academy of Chinese Medical Sciences, Hangzhou Qihan Biotech Co.,Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Hangzhou Qihan Biotech Co.,Ltd. | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1